AbCellera Advances TCE Platform & Strategic Partnerships
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
- Latest
- Trending
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Medicxi launches Alys Pharmaceuticals with $100m funding to develop groundbreaking therapies in immunodermatology. The company aims to address unmet needs ...
Diversity in biotechnology and venture capital is crucial for driving innovation and breakthroughs in healthcare, according to Dr. Stanley Lewis. ...
Efforts to diversify biotech venture capital funding could lead to innovation, breakthroughs in healthcare, and improved outcomes for minorities.
Protagenic Therapeutics achieves milestone in Phase I trial for PT00114, a compound for treating stress-related neuro-psychiatric disorders. No adverse reactions ...
Cleveland Clinic and IBM join forces to advance immunotherapy research through AI, unlocking new targets for cancer therapy. #Immunotherapy #AI ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.